Cargando…

Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy

PURPOSE: This study was performed to observe changes prospectively in exophthalmos and orbital fat in patients with inactive thyroid-associated ophthalmopathy (TAO) treated with bimatoprost. METHODS: In this 12-month single-treatment pilot observational study, 13 patients with inactive-phase TAO wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Higashiyama, Tomoaki, Ohji, Masahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267500/
https://www.ncbi.nlm.nih.gov/pubmed/30568419
http://dx.doi.org/10.2147/OPTH.S187164
_version_ 1783376089288015872
author Higashiyama, Tomoaki
Ohji, Masahito
author_facet Higashiyama, Tomoaki
Ohji, Masahito
author_sort Higashiyama, Tomoaki
collection PubMed
description PURPOSE: This study was performed to observe changes prospectively in exophthalmos and orbital fat in patients with inactive thyroid-associated ophthalmopathy (TAO) treated with bimatoprost. METHODS: In this 12-month single-treatment pilot observational study, 13 patients with inactive-phase TAO were administered bimatoprost to treat exophthalmos due to TAO. Exophthalmos values and orbital tissue volumes were measured on MRI by technicians in a masked fashion. RESULTS: Nine orbits of nine patients (eight women, one man) were treated with bimatoprost for 12 months. Mean exophthalmos values before and after treatment were 21.7±2.2 and 21.7±2.0 mm, respectively. The mean value after 12 months of treatment was not significantly different from before treatment (P=0.82). Mean orbital fat volume before and after 12 months of treatment was 17.2±2.5 and 17.0±3.0 cm(3), respectively. The corresponding total extraocular muscle volume was 4.0±0.7 and 3.8±0.9 cm(3), respectively. Mean volume in each tissue type after 12 months of treatment was not significantly different from before treatment (orbital fat, P=0.70; extraocular muscles, P=0.32). CONCLUSION: Topical bimatoprost treatment did not reduce exophthalmos or orbital fat in this cohort of patients with inactive TAO.
format Online
Article
Text
id pubmed-6267500
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62675002018-12-19 Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy Higashiyama, Tomoaki Ohji, Masahito Clin Ophthalmol Original Research PURPOSE: This study was performed to observe changes prospectively in exophthalmos and orbital fat in patients with inactive thyroid-associated ophthalmopathy (TAO) treated with bimatoprost. METHODS: In this 12-month single-treatment pilot observational study, 13 patients with inactive-phase TAO were administered bimatoprost to treat exophthalmos due to TAO. Exophthalmos values and orbital tissue volumes were measured on MRI by technicians in a masked fashion. RESULTS: Nine orbits of nine patients (eight women, one man) were treated with bimatoprost for 12 months. Mean exophthalmos values before and after treatment were 21.7±2.2 and 21.7±2.0 mm, respectively. The mean value after 12 months of treatment was not significantly different from before treatment (P=0.82). Mean orbital fat volume before and after 12 months of treatment was 17.2±2.5 and 17.0±3.0 cm(3), respectively. The corresponding total extraocular muscle volume was 4.0±0.7 and 3.8±0.9 cm(3), respectively. Mean volume in each tissue type after 12 months of treatment was not significantly different from before treatment (orbital fat, P=0.70; extraocular muscles, P=0.32). CONCLUSION: Topical bimatoprost treatment did not reduce exophthalmos or orbital fat in this cohort of patients with inactive TAO. Dove Medical Press 2018-11-27 /pmc/articles/PMC6267500/ /pubmed/30568419 http://dx.doi.org/10.2147/OPTH.S187164 Text en © 2018 Higashiyama and Ohji. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Higashiyama, Tomoaki
Ohji, Masahito
Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
title Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
title_full Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
title_fullStr Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
title_full_unstemmed Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
title_short Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
title_sort treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267500/
https://www.ncbi.nlm.nih.gov/pubmed/30568419
http://dx.doi.org/10.2147/OPTH.S187164
work_keys_str_mv AT higashiyamatomoaki treatmentwithbimatoprostforexophthalmosinpatientswithinactivethyroidassociatedophthalmopathy
AT ohjimasahito treatmentwithbimatoprostforexophthalmosinpatientswithinactivethyroidassociatedophthalmopathy